Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

5(62.5%)

Phase 1

3(37.5%)

8Total

Phase 2(5)

Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT02249429Phase 2Completed

Open-Label, Non Randomized Phase 2 Study With Safety Run-In

Role: lead

NCT02669511Phase 2Completed

PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Role: lead

NCT03127020Phase 2Completed

Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients

Role: lead

NCT02723877Phase 1Completed

PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)

Role: lead

NCT02483858Phase 1Completed

Study of Oral PQR309 in Patients With Advanced Solid Tumors

Role: lead

NCT03120000Phase 2Withdrawn

PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Role: lead

NCT02850744Phase 2Terminated

Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients

Role: lead

NCT01940133Phase 1Completed

A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PQR309

Role: lead

All 8 trials loaded